Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07135349) titled 'A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNa for the Treatment of Hepatitis B' on Aug. 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
Condition:
Chronic Hepatitis B
Intervention:
Drug: BW-20507 with/without NUC
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 15, 2025
Target Sample Size: 200
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/...